Chemistry:Opelconazole
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | PC-945 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C38H37F3N6O3 |
| Molar mass | 682.748 g·mol−1 |
Opelconazole (PC-945) is an experimental antifungal drug and the first triazole delivered via inhalation.[1][2][3] The drug is in Phase III and Phase II trials as of 2023.[4]
References
- ↑ Wiederhold, Nathan P. (August 2022). "Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents" (in en). Journal of Fungi 8 (8): 857. doi:10.3390/jof8080857. ISSN 2309-608X. PMID 36012845.
- ↑ Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (3 June 2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677.
- ↑ Ito, Kazuhiro (2022). "Inhaled antifungal therapy: benefits, challenges, and clinical applications". Expert Opinion on Drug Delivery 19 (7): 755–769. doi:10.1080/17425247.2022.2084530. PMID 35634895.
- ↑ "Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole". https://www.biospace.com/article/releases/pulmocide-announces-new-clinical-data-confirming-low-potential-for-drug-drug-interactions-with-inhaled-opelconazole/.
 |  |
